Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Towa to Discontinue Sales of 34 Products due to Bulk Drug Supply Problems, Weak Demand
November 1, 2017
- Sumitomo Dainippon In-Licenses Diabetes Med from France’s Poxel
November 1, 2017
- Astellas’ Half-Year Operating Profit Down 38.8% on LLP Divestiture, Micardis Gx Erosion
November 1, 2017
- Global Sales of Shionogi’s Novel Influenza Drug Could Reach US$1 Billion: President
November 1, 2017
- Parkinson’s Disease Therapy Rasagiline Improves Average Daily Off-Time in Japan PII/PIII Study: Takeda
November 1, 2017
- Daiichi Sankyo Pairs Up with German Startup to Develop ADC for Solid Cancer
November 1, 2017
- Boehringer, Astellas to Extend Sales Pact for Micardis Family of Products to March 2020
November 1, 2017
- Sumitomo Dainippon Beats 1st Half Guidance, Ups Full-Year Outlook
October 31, 2017
- Shionogi Notches Double-Digit Sales Rise on HIV/Flu Royalties
October 31, 2017
- JT, Torii to Jointly Develop HIF-PH inhibitor in Japan
October 30, 2017
- JCR Starts Development of Another BBB-Penetrating Drug for Hurler Syndrome
October 30, 2017
- Mogamulizumab Accepted for Review in Europe: Kyowa Kirin
October 30, 2017
- JSR Grabs License to Gut Bacteria Research Outcome by Keio Univ./Univ. of Tokyo, I/O Drug Discovery Eyed
October 30, 2017
- Crestor Generics of Sawai, Pfizer to Get Listed with Full Indications
October 27, 2017
- Eisai Ups Profit Estimates for April-September
October 27, 2017
- Ono Lifts Half-Year Guidance on Opdivo Boon
October 27, 2017
- Mitsubishi Tanabe Withdraws Petitions for Injunction against 3 Generic Makers Over Talion Patent Infringement
October 27, 2017
- Fujifilm Invests in Japan Biomedical to Boost Regenerative Medicine Business
October 27, 2017
- Novartis Seeks SJIA Indication for Ilaris in Japan
October 26, 2017
- Shionogi’s Sakigake-Designated Flu Med Filed in Japan
October 26, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…